The synthesis and characterization of new polymerizable pyrimidines: Immobilization of the monomers onto hydrophilic graft copolymeric supports through radiation-induced copolymerization-grafting by Pegiadou, S. et al.
The Synthesis and Characterization of New Polymerizable
Pyrimidines: Immobilization of the Monomers onto
Hydrophilic Graft Copolymeric Supports Through
Radiation-Induced Copolymerization–Grafting
S. PEGIADOU,1 J. T. GUTHRIE,2 M. H. GILL3
1The Department of Chemistry, The University of Thessaloniki, 54006 Thessaloniki, Greece
2The Department of Colour Chemistry, The University of Leads, Leads LS2 9JT, United Kingdom
3The Department of Chemistry, The University of Coimbra, Coimbra 3049, Portugal
Received 9 July 1997; accepted 18 January 1998
ABSTRACT: Polymerizable quaternary allyl-pyrimidinium salts, that is, 1-allyl-4-
amino-5-phenyl-pyrimidine (IV), 1-allyl-4-acetamido-5-phenyl-pyrimidine (V), 1-allyl-
5-hydroxymethylamino-5-phenyl-pyrimidine (VI), and 1-allyl-pyrimidine (VIII) bro-
mides, as well as 4-acrylamido-5-phenyl-pyrimidines II9 and IV9, were synthesized and
characterized. Three of the activated pyrimidine derivatives, the two acrylamido and
one allyl pyrimidine, were immobilized onto (Agar-g-co-HEMA)-X-TMPTA via graft
copolymerization. Each copolymer system, based on 2-hydroxyethyl methacrylate
(HEMA) grafted onto Agar followed by crosslinking with trimethyllopropane triacrylate
(TMPTA), was prepared by radiation-induced copolymerization carried out in the
simultaneous mode. The release properties of the immobilized pyrimidines were as-
sessed in various aqueous media over a period of approximately 22 days. © 1998 John
Wiley & Sons, Inc. J Appl Polym Sci 70: 211–218, 1998
Key words: allyl pyrimidines; quaternary pyrimidinium salts; quaternary allyl pyri-
midines; polymerizable allyl pyrimidines; acrylamido pyrimidines; immobilization of
polymerizable pyrimidines; graft copolymerization
INTRODUCTION
Various functional pyrimidines have been re-
ported. Pitha et al.1,2 and Ueda et al.3,4 have
described the preparation and polymerization of
various N-vinyl pyrimidines and purines. In their
studies, the authors used these linear polymers
together with the heterocyclic–base substituent
as model systems for nucleic acids. 5-Vinyl uracil
has been synthesized by Fyssekis et al.5 This
monomer was used in studies of the intermolecu-
lar forces, which originate in nucleic acids. It has
also been used to assist in the chromatographic
separation of nucleic acid components. Many ar-
ticles in this field have been published.6–12
However, information concerning allyl poly-
mers and copolymers based on the pyrimidine
and on the purine series is very limited. Allyl
polymers and copolymers generally have been
proposed for use as plasticizers, adhesives, and
also as crosslinking agents. Various patents have
been granted in such areas of application.13
There are several difficulties and peculiarities
that are inherent to the polymerization of allyl
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monomers. An example is given by the general
achievement of low-molar-mass polymers, arising
from free radical initiation routes because of the
ability of the allyl radical to self-stabilize through
resonance.13 There is also the possibility of cy-
clisation, leading to 5- or 6-membered ring struc-
tures, especially with diallyl amines during at-
tempts at free radical addition polymerization.14
Matsumoto et al.15–17 have reported anomalous
head-to-head addition sequences in the radical
polymerization of allylic monomers. In their
study, this group made comparisons with the cor-
responding vinyl monomers.
Paleos and coworkers18,19 have provided infor-
mation concerning the polymerization of allyl and
diallyl quaternary ammonium salts. This group
used irradiation procedures to provide polymers
whose mean molar mass values were approxi-
mately 11.000 6 1000 Daltons. The polymers, ob-
tained by polymerization of these surfactant mono-
mers, under micellar conditions, are interesting be-
cause of their application as drug carriers and as
biomimetic agents for reactivity control.
So the pyrimidine ring system, condensed or
otherwise, is still very interesting, because it has
been widely used in a variety of antibacterial
applications and other applications, including
drugs, antibiotics, analgesics, and antitumour
agents.20–23 Selective functionalization of the py-
rimidine ring provides the opportunity for its con-
version to a polymerizable system suitable for use
in an encapsulated or covalently attached form.
The subject of biocatalyst immobilization on
graft copolymeric supports is now well estab-
lished.24–28 Gel entrapment has also received a
great deal of attention.29–32 Each of these ap-
proaches is characterized by the development of a
suitable polymer matrix, consideration of immo-
bilization coupling procedures, assessment of cou-
pling effectiveness, features relevant to stability
and suitability for recycling, release mechanisms,
and the significance of microenvironmental fac-
tors.33,34
Our interests lie in immobilization biotechnol-
ogy, particularly with respect to cells and antibod-
ies35 and to enzymes.36–38
More recently, we have interested in the use of
covalent linkage, coupled with crosslinking, to
provide a means of effective immobilization of
selected drugs.39,40 When the support system is
highly hydrophilic, though still crosslinked, very
effective supports have been generated. In this
report, we describe our studies involving the syn-
thesis of selected allyl and acrylamido pyrimi-
dines containing reactive functional groups.
Characterization of the monomers has been un-
dertaken using spectroscopic and analytical tech-
niques. Three differently functionalized pyrimi-
dines have been immobilized, by entrapment–co-
valent linkage, onto a graft copolymer based on
2-hydroxyethylmethacrylate (HEMA), simulta-
neously grafted onto agar while the entire system
is subjected to controlled crosslinking using tri-
methylopropane triacrylate (TMPTA).41 The
product is symbolized as (Agar-g-co-HEMA)-X-
TMPTA.
EXPERIMENTAL
Reagents
Pyrimidine (Aldrich Chem. Co) was used as sup-
plied. Allyl bromide (Fluka Chem. purum) was used
as supplied. Formaldehyde solution was supplied
by BDH Chem. Ltd., Poole, UK. Acryloyl chloride,
formalin, and hydroxyethyl methacrylate were sup-
plied by Aldrich Chemical Co. Ltd., Gillingham,
UK. Trimethylopropane triacrylate was supplied by
U.C.B. (Belgium). The agar was obtained from Si-
comol Ltd., Figueira da Foz, Portugal.
Preparation of Starting Materials
The 4-amino-5-phenyl-pyrimidine (I) and 4-acet-
amido-5-phenyl-pyrimidine (II) were prepared ac-
cording to the procedures described in the lit-
erature.42–44 For the 4-hydroxymethylamino-5-
phenyl-pyrimidine (III) 1.71 g (0.01 mol) of (I) was
added to 15 cm3 of formaldehyde solution (30%),
heated gently for 10 min until the sample was
completely dissolved and then cooled with stir-
ring over 30 min. The solution was poured into
cooled water and chilled to 5°C overnight. The
resulting precipitate was filtered, washed with
cold water, and then dried at 60°C.45 The result-
ing white crystals (yield 77%) gave the following
information.
Melting point (mp): 135–136°C; Infrared (IR) analysis
(KBr) cm21, 3300 (NH); 3100 (OH); 1580 (C¢N). Nu-
clear magnetic resonance (NMR): (CDCl3, d) 8.58 S
(1H); 8.11 S (1H); 7.50–7.58 m (5H); 6.07 Sbr (1H);
4.93 d (2H). Mass spectroscopy (MS): m/z, 201 (14) M1;
183 (20); 170 (100); 156 (19); 143 (17); 128 (15); 117 (10);
102 (45).
ANAL. Calcd for C11H11ON3: C, 65.67 %; H, 5.4 %; N,
20.89% Found: C, 65.65%; H, 5.5%; N, 20.85%.
The monomers’ syntheses are summarized in
Scheme 1
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The structural assignments of the monomers
(IV), (V), (VI), and (VIII) were made on the basis
of elemental and spectroscopic analysis (IR,
NMR, MS) of the purified products, and the re-
sults are summarized in Table I.
The IR spectra were obtained using a UNICAM
SP 1100 spectrophotometer. NMR spectra re-
ported in d units, were recorded on a JEOL FX 90
Q, and the mass spectra were measured using a
KRATOS MS-25 mass spectrometer at an ioniza-
tion energy of 50 eV.
Elemental analysis were performed with a Carlo
Erba analyzer, Model 1106. The specific synthesis
procedures of the monomers are as follows. For
1-Allyl-4-amino-5-phenyl pyrimidine bromide (IV),
1-Allyl-4-acetamido-5-phenyl pyrimidine bromide
(V), 1-Allyl-4-hydroxymethylamino-5-phenyl py-
rimidine bromide (VI), and 1-Allyl-pyrimidine bro-
mide (VIII), 0.01 mol of parent compounds (I), (II),
(III), and (VII), respectively, and 0.015 mol of allyl
bromide were added to 20 cm3 of ethyl acetate for
the synthesis of compounds (IV), (V), and (VI).
MeOH was used in the synthesis of compound
(VIII). The quaternization were carried out with
stirring over 24 h for compound VIII and under
reflux 4 h for (V) and (VI). The quaternary salts
were precipitated after cooling the residue.19 Re-
crystallization occurred using water. White crystals
were obtained. The progress of the reactions was
checked using thin layer chromatography (silica gel;
methanol : chloroform 1 : 1).
Synthesis of 4-N-(Bis)Acrylamido-5-phenyl-
pyrimidine [Compound (II*)] and 4-N-(Acrylamido)
aminomethyl-acrylyl 5-phenyl-pyrimidine
[Compound (IV *)]
0.01 Mol of the compounds I or III (see Scheme 2)
respectively were added to 20 cm3 of a 20% KOH
solution in 7 cm3 of dioxan. Acryloyl chloride
(2 cm3) was poured into this suspension with stir-
ring. The mixture was cooled with occasional
shaking for about 10 minutes.
A further 2 cm3 of acryloyl chloride were then
added to the mixture. The reaction was cooled
with occasional shaking. The products were
poured into 20 cm3 of chilled water. The resulting
precipitate was filtered, washed with cold water
and dried under vacuum at 40° C.
Compound (II9) A yellow powder was obtained
with a yield of 45%. The melting range was
156 –158° C. The I.R. analysis in KBr show
peaks at 3300 cm21 for the NH group, 1650
cm21 for the C 5 O group and 1850 cm21 for
the–C 5 N– group.
Scheme 1
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M.S.: m/z 279 (1) M1; 225 (5), 196 (12), 170
(100), 155 (4), 143 (21), 128 (4), 117 (13), 102 (15).
Analysis: (%) for C16H13O2N3: Calculated: C,
68.88; H, 4.6; N, 15.05 Found: C, 68.35; H, 4.8; N,
15.25
Compound (IV9) Yellow powder (yield 40%) with
m.p. 5 155–157°C. I.R. (KBr) cm1 3400 (NH),
1650 (C 5 O), 1580 (C 5 N) M.S.: m/z 279 (1.5)
(M5–HCHO), 225 (6), 197 (11), 170 (100), 155 (5),
143 (24), 128 (5), 117 (19), 102 (24). 128 (5), 117
(19), 102 (24). Analysis (%) for C17H15O3N3: Cal-
culated: C 66.01, H 4.85, N 13.59 Found: C 65.80,
H 4.50, N, 13.2
Problems in solubility meant that it was not
possible to acquire NMR spectra for monomeric
products II9 and IV9. However, characteristic
mass spectra were obtained for these 2 mono-
mers. Those monomers syntheses are summa-
rized in Scheme 2.
Table I Elemental Analysis, Spectral Data, Yields, and Melting Points (mp) of Monomers
IV, V, VI, and VIII
Compound Formula Yield mp Spectral Data Elemental Analysis
IV C13H14N3Br 90% 233–234°C IR (KBr) cm
21:3300 (NH2);
3120 (C¢C); 1650 (C¢N);
NMR (D2O, d):8.69 S
(1H); 8.66 S (1H); 7.50–
8.10 m (5H); 5.10–6.30
m (1H); 4.80 tr. (2H);
4.60 d (2H). MS: m/z
250 (40); 210 (100); 170
(63); 143 (15); 143 (15);
102 (17); 80 (18).
Calc:C, 53.42%; H, 4.79%;
N, 14.38%; Br, 27.39%.
Found: C, 53.75%; H,
4.85%; N, 14.85%; Br,
27.40%.
V C15H16ON3Br 65% 157–158°C IR (KBr) cm
21:3450 (NH);
3000 (C¢C); 1730 (C¢O);
1650 (C¢N). NMR
(CDCl3, d):9.25 S (1H);
9.01 S (1H); 7.71–7.53 m
(5H); 6.39–6.22 m (1H);
6.12 tr. (2H); 5.11 d
(2H); 2.32 S (3H). MS:
m/z 213 (30); 201 (20);
170 (100); 156 (30); 128
(30); 102 (38); 80 (13).
Calc:C, 53.89%; H, 4.79%;
N, 12.57%; Br, 23.95%.
Found: C, 53.75%; H,
4.75%; N, 12.40%; Br,
24.05%.
VI C14H16ON3Br 70% 162–163°C IR (KBr) cm
21:3450 (NH);
3300 (OH); 1650 (C¢N);
1600 (C¢N). NMR
(CDCl3, d):9.04 S (1H);
8.63 S (1H); 8.18 d (2H);
8.14 d (1H); 7.98–7.63 m
(5H); 6.12–5.60 m (1H);
5.10 tr. (2H); 5.02 quat.
(4H); 3.10 Sbr. (1H). MS:
m/z 201 (18); 182 (27);
170 (100); 156 (37); 142
(22); 128 (25); 102 (48);
80 (4).
Calc:C, 52.17%; H, 4.96%;
N, 13.04%; Br, 24.84%.
Found: C, 52.0%; H,
5.05%; N, 13.3%; Br,
25.05%.
VIII C7H9N2Br 20% 139–140°C IR (KBr) cm
21:3000 (C¢C);
1640 (C¢N). NMR (D2O,
d):9.72 S (1H); 9.47 d
(1H); 9.31 d (1H); 8.28
tr. (1H); 6.78–6.25 m
(1H); 5.61 tr. (2H);
5.40 d (2H).
Calc:C, 41.79%; H, 4.47%;
N, 13.93%; Br, 39.80%.
Found: C, 41.35%; H,
4.55%; N, 14.10%; Br,
39.70%.
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The compounds II9, IV9, and V (100 mg) were
immobilized by radiation-included copolymeriza-
tion onto (Agar-g-co-HEMA)-x-TMPTA, as indi-
cated above.
Polymerization Procedures
The pyrimidine derivatives (II9, IV9, or V) (100
mg) were dissolved in a dimethyl-formamide
Scheme 2
Figure 1 Variation in the release of compound II9 with time in various aqueous
solutions: (F) physiological serum; (E) distilled water; (h) 0.1M phosphate buffer, pH
7.3; (n) 0.01M HCl.
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solution (30 cm3) containing 1.0 g of HEMA and
0.2 g of TMPTA. Then, 1.0 g of agar was intro-
duced in this solution. The suspension was ir-
radiated at 18.3 rad s21 for 24 h at 25°C, in the
presence of air, on a 60Co isotope source. The
suspension was filtered and thoroughly washed
with dimethylformamide and with water. The
powder was then dried at constant weight, un-
der vacuum at 40°C. These procedures were
repeated.
Figure 2 Variation in the release of compound IV9 with time in various aqueous
solutions: (F) physiological serum; (E) distilled water; (h) 0.1M phosphate buffer, pH
7.3; (n) 0.01M HCl.
Figure 3 Variation in the release of compound V with time in various aqueous
solutions: (F) physiological serum; (E) distilled water; (h) 0.1M phosphate buffer, pH
7.3; (n) 0.01M HCl.
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Release Determination of the Immobilized
Pyrimidine Derivatives
The samples containing the pyrimidine deriva-
tives (prepared by irradiation, as indicated above)
(50 mg) were separately introduced in 5 cm of
various aqueous media [distilled water, physio-
logical serum, 0.1M phosphate buffer (pH 5 7.0),
and 1022M HCl]. After known intervals of time,
the samples were filtered and subsequently ana-
lyzed spectrophotometrically at l 5 400 (for sam-
ples II9 and IV9) and at l 5 345 for the sample V.
RESULTS AND DISCUSSION
The 3 monomers (IV), (V), and (VI) showed, in IR,
peaks at 3400–3300 cm21 for the NH group and
all 4 allyl monomers peaks at 3100–3000 cm21 for
allylic C¢C group and peaks for C¢N (arom) at
1650–1600 cm21.
The 1H-NMR spectra of all quaternary salts
(IV, V, VI, and VIII) gave pyrimido protons peaks
at d 8.28–9.10 S and d 9.04–9.72 S and multiple
peaks for aromatic protons of the phenyl group at
d 8.10–7.50. The allylic protons gave almost the
same pattern, that is, peaks at d 4.60–5.40 (dou-
blet) corresponding to N1-CH2 protons, peaks at d
5.10–6.12 (triplet) corresponding to C¢CH2 pro-
tons and peaks at d 5.10–6.78 (multiplet) for the
CH¢CH2 proton.
The mass spectra of compounds (IV), (V), and
(VI) showed the same fragmentation pattern, al-
though as it is well known for the quaternary
salts, generally, there is not a molecular ion peak.
For 1 g aliquots of agar and 1 g aliquots of
HEMA, together with 0.2 g of TMPTA, the (%)
grafting yields were 73.0, 59.6, and 59.6 for the
pyrimidine compounds II9, IV9, and V, respec-
tively. This confirms that highly satisfactory
yields were obtained in the copolymerization re-
actions.
The release characteristics of the pyrimidine
compounds, after being immobilized, were as-
sessed in various aqueous solutions for 22 days.
From the analysis of the results indicated in
Figures 1–3 and Table II, we suggest that good
yields of immobilization of the activated pyrimi-
dines were obtained. It is clear that the water-
soluble pyrimidine (V) is released more easily
than is the less water-soluble compound (IV9).
It is also clear that compound V gives similar
levels of release in each of the continuous, storage
media over the 22-day period (Fig. 3). Compounds
II9 and IV9 show similar release behaviors in both
neutral and acidic media (0.1M phosphate buffer
and 0.01M HCl, respectively). However, the rate of
release is more pronounced for compound IV9 than
it is for compound II9 at equivalent periods of time.
Compound IV9 shows a rapid release profile from
day 1 in 0.01M phosphate buffer and 0.01M HCl.
This level of initial release is greater than that
obtained, even with the water-soluble pyrimidine
compound V.
Compounds II9 and IV9 show a slower, more
continuous release behavior in physiological se-
rum and in distilled water. Here, the behavior of
compound IV9 in physiological serum can be sin-
gled out for its very slow release characteristics.
Table II Release of Pyrimidine Derivative (% of Original Bound) After 22 Days,
in Various Aqueous Media
Pyrimidine
Compound Medium
Released
Compound (g21)
Copolymer (mg)
Percentage Released
Relative to Initial Mass
of Compound Immobilized
II9 H2O; 0.1M phosphate;
buffer pH 5 7.3;
0.01M HCl;
physiological serum
33.7
37.5
41.2
24.7
56.6
63.0
69.2
41.5
IV9 H2O; 0.1M phosphate;
buffer pH 5 7.3;
0.01M HCl
physiological serum
47.3
68.7
68.0
24.8
64.4
94.1
93.2
34.2
V H2O; 0.1M phosphate;
buffer pH 5 7.3;
0.01M HCl
physiological serum
70
67.3
64.8
59.7
95.9
92.8
88.8
81.8
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We should recall that while the experimental
stages are duplicated, one cannot regulate the
specific nature of the crosslinked, copolymeric as-
sembly. Though the average extent of grafting–
crosslinking may be identical on repetition, the
location of such grafts and crosslinks could differ.
This difference could influence the morphological
nature of the drug-support composite.
The graft copolymers show promise with re-
spect to their use in the immobilization of drugs.
However, further parameters need to be consid-
ered. These include the influence of the monomer
feed ratios, the temperature of reaction, and the
dose rate on the composition of the copolymers.
Such compositional variations will, in turn, influ-
ence the resulting immobilization capability and
also the release characteristics of the immobilized
drug composite.
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